A.R.T. Advisors’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

A.R.T. Advisors’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-61,388	Closed	-$555K	–	1774
2013 Q4	$555K	Sell	61,388 -62,011	-50%	-$448K	0.03%	735
2013 Q3	$777K	Sell	123,399 -19,966	-14%	-$127K	0.04%	606
2013 Q2	$977K	Buy	+143,365	New	+$999K	0.03%	637

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

A.R.T. Advisors's CADX Position: Q1 2014 in Review

A.R.T. Advisors sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 61,388 shares — an estimated $555K sold.

A.R.T. Advisors first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $977K in Q2 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

A.R.T. Advisors reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
A.R.T. Advisors sold 61,388 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $555K.
A.R.T. Advisors first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
A.R.T. Advisors's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $977K in Q2 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on A.R.T. Advisors's 13F filing for Q1 2014, filed 15 May 2014.